SCHEMBL4192389

SCHEMBL4192389

Cc1sc(-c2ccc(C(=O)O)cc2)nc1OCC(=O)NC1CCC(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RARB P10826 6/20 0.61
RARG P13631 4/20 0.61
RARA P10276 3/20 0.54
LMNA P02545 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190628 0.92 RARB (0.63) RARBRARGRARALMNASMN1; SMN2
SCHEMBL4326646 0.91 RARB (0.62) RARBRARGRARALMNASMN1; SMN2
SCHEMBL4184893 0.91 RARB (0.62) RARBRARGRARALMNASMN1; SMN2
SCHEMBL4187456 0.87 RARB (0.62) RARBRARGRARALMNASMN1; SMN2
SCHEMBL4630465 0.80 RARB (0.51) RARBRARGRARALMNASMN1; SMN2
SCHEMBL4196901 0.77 RARB (0.92) RARBRARGRARALMNAALDH1A1
SCHEMBL4190248 0.76 RARB (0.73) RARBRARGRARALMNASMN1; SMN2
SCHEMBL4190671 0.76 RARB (1.00) RARBRARGRARACSNK2A2CSNK2A1
SCHEMBL4183477 0.75 RARB (0.62) RARBRARGRARALMNAMAPK1
SCHEMBL4188775 0.70 RARB (1.00) RARBRARGRARAHRH3CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220296579-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS CORNELL UNIVERSITY (US) 2022-09-22 US disclosed
US-11191755-B2 Compositions and methods for providing cardioprotective effects CORNELL UNIVERSITY (US) 2021-12-07 US disclosed
US-11160769-B2 Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists CORNELL UNIVERSITY (US) 2021-11-02 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS SONY CORPORATION (JP) 2009-07-09 US disclosed
EP-1907347-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS Arcadia Pharmaceuticals Inc. (US) 2008-04-09 EP disclosed
WO-2007009083-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-01-18 WO disclosed
WO-2007009083-A2 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220296579-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-11191755-B2 Compositions and methods for providing cardioprotective effects RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-11160769-B2 Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists RARA, RARG, RXRA RARB 5/4885RARG 2/4885RARA 1/4885
US-20090176837-A1 COMPOUNDS WITH ACTIVITY AT RETINOIC ACID RECEPTORS RARB, RARA, RARG RARB 1/4885RARG 3/4885RARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.